Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared With Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients
NCT ID: NCT00402428
Last Updated: 2013-08-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
1331 participants
INTERVENTIONAL
2006-12-31
2009-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
180 mcg PEG-IFNx2a every 1 week (48 doses) + Ribavirin 1000 or 1200 mg/day
peginterferon alfa-2a
180 mcg once a week for 48 weeks
Ribavirin
1000 mg/day(for subjects \<75kg) or 1200 mg/day (for subjects
=,\> 75kg)
2
900 mcg alb-IFN every 2 weeks (24 doses)+ Ribavirin 1000 or 1200 mg/day
albumin interferon alfa-2b
900 mcg or 1200mcg every two week for 48 weeks
Ribavirin
1000 mg/day(for subjects \<75kg) or 1200 mg/day (for subjects
=,\> 75kg)
3
1200 mcg alb-IFN every 2 weeks (24 doses)+ Ribavirin 1000 or 1200 mg/day
albumin interferon alfa-2b
900 mcg or 1200mcg every two week for 48 weeks
Ribavirin
1000 mg/day(for subjects \<75kg) or 1200 mg/day (for subjects
=,\> 75kg)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
albumin interferon alfa-2b
900 mcg or 1200mcg every two week for 48 weeks
peginterferon alfa-2a
180 mcg once a week for 48 weeks
Ribavirin
1000 mg/day(for subjects \<75kg) or 1200 mg/day (for subjects
=,\> 75kg)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Liver biopsy performed within 2 years of Day 0 or during screening.
* Infected with hepatitis C virus genotype 1.
* Interferon alfa treatment naïve (ie, have never been treated with an interferon product).
* Subjects are eligible to enter the study if they (or their partners) are not pregnant or nursing, are sterile, or of non childbearing potential, or are willing to practice abstinence or use appropriate birth control methods during the study and for 7 months after the last dose of ribavirin.
* Have compensated liver disease.
Exclusion Criteria
* History of moderate, severe or uncontrolled psychiatric disease, especially depression, including a history of hospitalization or prior suicidal attempt.
* Positive for human immunodeficiency virus (HIV-1) or hepatitis B surface antigen (HBsAG).
* Clinical diagnosis of other causes of chronic liver disease including but not limited to hepatitis B, autoimmune hepatitis, primary biliary cirrhosis, alcoholic liver disease, hemochromatosis, Wilson's Disease, or alpha 1-antitrypsin deficiency.
* A history of immunologically mediated disease (eg, rheumatoid arthritis, inflammatory bowel disease, moderate/severe psoriasis, sarcoidosis, systemic lupus erythematosus).
* Active seizure disorder within the last 2 years.
* Organ transplant other than cornea and hair transplant.
* Clinically significant hemoglobinopathy (eg, thalassemia, sickle cell anemia).
* Cancer within the last 5 years(with the exception of adequately treated basal cell carcinoma of the skin or in situ carcinoma of the uterine cervix).
* Drug or alcohol addiction within the last 6 months. Subjects in a supervised methadone treatment program may be enrolled in the study.
* Received any experimental agent within 28 days prior to Day 0.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis
INDUSTRY
Human Genome Sciences Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alabama at Birmingham
Birmingham, Alabama, United States
Mayo Clinic Hospital
Phoenix, Arizona, United States
UCSF Fresno
Fresno, California, United States
Scripps Clinic
La Jolla, California, United States
USC Keck School of Medicine
Los Angeles, California, United States
Cedars-Sinai Medical Center
Los Angeles, California, United States
UCLA / West LA VAMC
Los Angeles, California, United States
Huntington Medical Research Institutes
Pasadena, California, United States
University California-San Diego
San Diego, California, United States
San Diego Digestive Diseases Consultants, Inc
San Diego, California, United States
VA San Diego Healthcare
San Diego, California, United States
California Pacific Medical Center
San Francisco, California, United States
University of California at San Francisco
San Francisco, California, United States
University of Colorado
Denver, Colorado, United States
University of Colorado Health Sciences Ctr
Englewood, Colorado, United States
Walter Reed Army Medical Center
Washington D.C., District of Columbia, United States
University of Florida - Gainesville
Gainesville, Florida, United States
Shands Jacksonville Medical Center
Jacksonville, Florida, United States
Mayo Clinic Transplant Center
Jacksonville, Florida, United States
Va Health Care System
Miami, Florida, United States
University of Miami
Miami, Florida, United States
Venture Research Institute
North Miami Beach, Florida, United States
University Hepatitis Center
Sarasota, Florida, United States
Atlanta Gastroenterology Associates
Atlanta, Georgia, United States
GI of Atlanta
Atlanta, Georgia, United States
Northwest Georgia Gastroenterology Associates
Marietta, Georgia, United States
Alan D Tice, MD, LLC
Honolulu, Hawaii, United States
Northwestern Memorial Hospital
Chicago, Illinois, United States
Indiania University School of Medicine
Indianapolis, Indiana, United States
University of Iowa Hospitals and Clinics
Iowa City, Iowa, United States
University of Louisville
Louisville, Kentucky, United States
Tulane University Health Sciences Center
New Orleans, Louisiana, United States
University of Maryland
Baltimore, Maryland, United States
Johns Hopkins Center for Viral Hepatits
Baltimore, Maryland, United States
Maryland Digestive Disease Center
Laurel, Maryland, United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Henry Ford Health System
Detroit, Michigan, United States
Mayo Clinic
Rochester, Minnesota, United States
Digestive Health Specialist
Tupelo, Mississippi, United States
St. Louis University
St Louis, Missouri, United States
University of New Mexico
Albuquerque, New Mexico, United States
North Shore University Hospital
Manhasset, New York, United States
New York Hospital - Cornell
New York, New York, United States
Faculty Practice Associates
New York, New York, United States
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States
Duke Medical Center
Durham, North Carolina, United States
University of Cincinnati
Cincinnati, Ohio, United States
Hospital of University of PA
Philadelphia, Pennsylvania, United States
Thomas Jefferson University
Philadelphia, Pennsylvania, United States
Memphis Gastroenterology Group
Germantown, Tennessee, United States
Nashville Gastroenterology
Nashville, Tennessee, United States
Nashville Gastrointestinal Specialists
Nashville, Tennessee, United States
Liver Institute at Methodist Dallas
Dallas, Texas, United States
Baylor University Medical Center
Dallas, Texas, United States
UT Southwesten Medical Center
Dallas, Texas, United States
Brooke Army Medical Center
Fort Sam Houston, Texas, United States
GI & Liver Assoicates
Granbury, Texas, United States
Liver Specialist of Texas
Houston, Texas, United States
Alamo Medical Research
San Antonio, Texas, United States
INOVA Fairfax Hospital
Annandale, Virginia, United States
Metropolitan Research
Fairfax, Virginia, United States
Virginia Commonwealth University Medical Ctr
Richmond, Virginia, United States
University of Washington
Seattle, Washington, United States
University of Wisconsin-Madison
Madison, Wisconsin, United States
Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia
Concord Repatriation General Hospital
Concord, New South Wales, Australia
St George Hospital Clinical School of Medicine University of New South Wales
Kogarah, New South Wales, Australia
John Hunter Hospital
New Lambton, New South Wales, Australia
Westmead Hospital
Westmead, New South Wales, Australia
Greenslopes Private Hospital
Greenslopes, Queensland, Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia
Monash Medical Centre
Clayton, Victoria, Australia
St Vincent's Hospital
Fitzroy, Victoria, Victoria, Australia
Western Hospital
Footscray, Victoria, Australia
Austin Hospital
Heidelburg, Victoria, Australia
The Alfred Hospital
Melbourne, Victoria, Australia
Royal Melbourne Hospital
Parkville, Victoria, Australia
Fremantle Hospital
Fremantle, Western Australia, Australia
Sir Charles Gairdner Hospital
Nedlands, Western Australia, Australia
Royal Perth Hospital
Perth, , Australia
Medizinische Universitätsklinik Graz
Graz, , Austria
Univ.-Klinik fuer Innere Medizin
Innsbruck, , Austria
Medical University of Vienna
Vienna, , Austria
Heritage Medical Research Clinic
Calgary, Alberta, Canada
University of Alberta
Edmonton, Alberta, Canada
University of Alberta Hospital
Edmonton, Alberta, Canada
Vancouver General Hospital
Vancouver, British Columbia, Canada
University of Manitoba Health Sciences Centre
Winnipeg, Manitoba, Canada
Dalhousie University
Halifax, Nova Scotia, Canada
University of Western Ontario Hospital
London, Ontario, Canada
Ottawa Hospital - General Campus
Ottawa, Ontario, Canada
Toronto General Hospital
Toronto, Ontario, Canada
Toronto Western Hospital
Toronto, Ontario, Canada
McGill University
Montreal, Quebec, Canada
Klinika infekcních chorob
Brno, , Czechia
Klinika Infekcních nemocí
Hradec Králové, , Czechia
Nemocnice s poliklinikou Melník
Mělník, , Czechia
Slezská nemocnice
Opava, , Czechia
Vseobecna fakultní nemocnice
Prague, , Czechia
Nuselská poliklinika
Prague, , Czechia
Ambulance pro interni a infekcni nemoci
Ústí nad Labem, , Czechia
Hopital Beaujon
Clichy, , France
Hopital Henri Mondor
Créteil, , France
CHU de Lyon, Hôpital de l'Hôtel Dieu
Lyon, , France
Hopital Saint-Joseph
Marseille, , France
Hopital de La Source
Orléans, , France
Hôpital Saint-Antoine
Paris, , France
Hopital Pitie-Salpetriere
Paris, , France
Hopital Haut-Leveque
Pessac, , France
CHU Purpan Clinique Dieulafoy
Toulouse, , France
Hôpital de Brabois
Vandœuvre-lès-Nancy, , France
UH Charite Berlin / Virchow Klinikum
Berlin, , Germany
Center for HIV and Hepatogastroenterology
Düsseldorf, , Germany
Universitätsklinik Düsseldorf
Düsseldorf, , Germany
UH Essen
Essen, , Germany
Klinikum der Johann Wolfgang Goethe-Universitaet
Frankfurt am Main, , Germany
Albert-Ludwigs-Universitaet Freiburg
Freiburg im Breisgau, , Germany
Medizinische Hochschule Hannover (MHH)
Hanover, , Germany
Universitätsklinikum Heidelberg
Heidelberg, , Germany
Universitätsklinikum Leipzig
Leipzig, , Germany
Johannes Gutenberg-Universitaet Mainz
Mainz, , Germany
Paracelsus Klinik der Stadt Marl
Marl, , Germany
Dayanand Medical College and Hospital
Ludhiana, , India
Jaslok Hospital and Research Centre and Breach Candy Hospital,
Mumbai, , India
G.B.Pant Hospital
New Delhi, , India
Bnei-Zion Medical Center
Haifa, , Israel
Rambam Health Care Campus
Haifa, , Israel
Hadassah Medical Organization
Jerusalem, , Israel
Holy Family Hospital
Nazareth, , Israel
Rabin Medical Center Beilinson Campus
Petah Tikva, , Israel
Tel Aviv Sourasky Medical Center
Tel Aviv, , Israel
Policlinico S.Orsola Malpighi
Bologna, , Italy
IRCCS Ospedale Maggiore, Fondazione Policlinico Mangiagalli e Regina Elena, Università di Milano
Milan, , Italy
Seconda Università di Napoli c/o Secondo Policlinico
Napoli, , Italy
Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone
Palermo, , Italy
I.R.C.C.S. Policlinico S. Matteo Università degli Studi di Pavia
Pavia, , Italy
Casa Sollievo della Sofferenza IRCCS
San Giovanni Rotondo (FG), , Italy
Azienda Ospedaliera S. Giovanni Battista Molinette
Torino, , Italy
Wojewódzki Szpital Specjalistyczny im.K. Dłuskiego
Bialystok, , Poland
Szpital Specjalistyczny
Chorzów, , Poland
Wojewódzki Szpital Zespolony
Kielce, , Poland
Szpital Uniwersytecki w Krakowie
Krakow, , Poland
Uniwersytet Medyczny
Lodz, , Poland
Akademia Medyczna
Warsaw, , Poland
Wojewódzki Szpital Zaka?ny
Warsaw, , Poland
Wojewódzki Szpital Specjalistyczny im. J. Gromkowskiego
Wroclaw, , Poland
Fundacion de Investigacion de Diego
Santurce, , Puerto Rico
Spitalul Clinic Colentina
Bucharest, , Romania
Institutul Clinic Fundeni
Bucharest, , Romania
Spitalul Clinic Dr.Victor Babes
Bucharest, , Romania
Spitalul Clinic de Adulti Cluj-Napoca
Cluj-Napoca, , Romania
Institutul de Gastroenterologie si Hepatologie
Lasi, , Romania
Hospital Universitari Germans Trias i Pujol
Badalona - Barcelona, , Spain
Hopital Universitari Vall d'Hebron
Barcelona, , Spain
Hospital Clinic i Provincial
Barcelona, , Spain
Hospital Universitario La Princesa
Madrid, , Spain
Hospital General Universitario Gregorio Marañón
Madrid, , Spain
Hospital Carlos III
Madrid, , Spain
Consorcio Hospital General Universitario de Valencia
Valencia, , Spain
Queen Elizabeth Medical Centre
Birmingham, , United Kingdom
Royal London Hospital
London, , United Kingdom
Imperial College London St Mary's Hospital Campus
London, , United Kingdom
Nottingham University Hospitals NHS Trust Queens Medical Centre Campus
Nottingham, , United Kingdom
Derriford Hospital
Plymouth, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Bain VG, Yoshida EM, Kaita KD, Swain MG, Heathcote EJ, Garcia A, Moore PA, Yu R, McHutchison JG, Subramanian GM. Dynamics of interferon-specific gene expression in peripheral blood of interferon alfa-naive patients with genotype 1 chronic hepatitis C infection treated with albumin-interferon alfa. Hepatol Res. 2006 Aug;35(4):256-62. doi: 10.1016/j.hepres.2006.04.005. Epub 2006 May 30.
Bain VG, Kaita KD, Yoshida EM, Swain MG, Heathcote EJ, Neumann AU, Fiscella M, Yu R, Osborn BL, Cronin PW, Freimuth WW, McHutchison JG, Subramanian GM. A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients. J Hepatol. 2006 Apr;44(4):671-8. doi: 10.1016/j.jhep.2005.12.011. Epub 2006 Jan 30.
S. Zeuzem, , Y. Benhamou, , D. Shouval, , V. Bain, S. Pianko, , R. Flisiak, , M. Grigorescu, , V. Rehak, , E. Yoshida, K. Kaita, , C. Hezode, A.U. Neumann, M. Subramanian, J. McHutchison. Interim (Week 12) Phase 2B Virological Efficacy and Safety Results of albumin interferon alfa-2b Combined with Ribavirin in Genotype 1 Chronic Hepatitis C Infection. EASL, 2006
Vinod Rustgi, et al. A Dose-Escalation Study of albumin alfa-Ribavirin in Non-responders to Prior Interferon Based Therapy for Chronic Hepatitis C Infection Phase 2 Dose A Phase 2 Dose-Escalation Study of albumin interferon alfa interferon alfa-2b Combined with 2b Combined with Ribavirin in Non Non-responders to Prior Interferon. EASL, 2006
Balan V, Nelson DR, Sulkowski MS, Everson GT, Lambiase LR, Wiesner RH, Dickson RC, Post AB, Redfield RR, Davis GL, Neumann AU, Osborn BL, Freimuth WW, Subramanian GM. A Phase I/II study evaluating escalating doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapy. Antivir Ther. 2006;11(1):35-45.
Zeuzem S, Sulkowski MS, Lawitz EJ, Rustgi VK, Rodriguez-Torres M, Bacon BR, Grigorescu M, Tice AD, Lurie Y, Cianciara J, Muir AJ, Cronin PW, Pulkstenis E, Subramanian GM, McHutchison JG; ACHIEVE-1 Study Team. Albinterferon Alfa-2b was not inferior to pegylated interferon-alpha in a randomized trial of patients with chronic hepatitis C virus genotype 1. Gastroenterology. 2010 Oct;139(4):1257-66. doi: 10.1053/j.gastro.2010.06.066. Epub 2010 Jun 27.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ACHIEVE-1
Identifier Type: OTHER
Identifier Source: secondary_id
HGS1008-C1060
Identifier Type: -
Identifier Source: org_study_id